Ligelizumab

N/A

Report date: 2025/03/12 13:46:12

Base Information

Drug NameLigelizumab
Drug Alias NameQGE-031
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunoglobulin E inhibitors
TargetsImmunoglobulin E
Therapy Area/IndicationsPeanut HypersensitivityFood HypersensitivityHypersensitivity +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTanox Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic Urticaria
Inactive IndicationsPeanut HypersensitivityFood HypersensitivityHypersensitivity +[7] 

Other Information

ATC CodeN/A
Related LinksWikipedia